Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways [9]

Leukemia

Volumn 20, Issue 1, 2006, Pages 151-154

  Yin, B ^a   Morgan, K ^a   Hasz, D E ^a   Mao, Z ^a   Largaespada, D A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYTARABINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROPIDIUM IODIDE; PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME INHIBITION; GENE INACTIVATION; LETTER; LEUKEMIA CELL LINE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME; WILD TYPE; ACUTE DISEASE; ANIMAL; CELL DEATH; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; MYELOID LEUKEMIA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACUTE DISEASE; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CYTARABINE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBROMIN 1; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 33644974752     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404033     Document Type: Letter

References (8)

1. Cros E, Jordheim L, Dumontet C, Galmarini CM. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1123-1132.
2. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3: 203-209.
3. Largaespada DA, Shaughnessy Jr JD, Jenkins NA, Copeland NG. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995; 69: 5095-5102.
4. Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12: 137-143.
5. Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003; 97: 441-449.
6. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
7. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573-8578.
8. Milella M, Kornblau SM, Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 160-190.